Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1254

1.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

Wingerchuk DM, Carter JL.

Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.

PMID:
24485135
2.

Teriflunomide for multiple sclerosis.

He D, Zhang C, Zhao X, Zhang Y, Dai Q, Li Y, Chu L.

Cochrane Database Syst Rev. 2016 Mar 22;3:CD009882. doi: 10.1002/14651858.CD009882.pub3. Review.

PMID:
27003123
3.

Teriflunomide for multiple sclerosis.

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;3:CD009882.

PMID:
23235682
4.

Established and novel disease-modifying treatments in multiple sclerosis.

Cross AH, Naismith RT.

J Intern Med. 2014 Apr;275(4):350-63. doi: 10.1111/joim.12203. Epub 2014 Mar 11. Review.

5.

Rituximab for relapsing-remitting multiple sclerosis.

He D, Guo R, Zhang F, Zhang C, Dong S, Zhou H.

Cochrane Database Syst Rev. 2013 Dec 6;(12):CD009130. doi: 10.1002/14651858.CD009130.pub3. Review.

PMID:
24310855
6.

Dimethyl fumarate for multiple sclerosis.

Xu Z, Zhang F, Sun F, Gu K, Dong S, He D.

Cochrane Database Syst Rev. 2015 Apr 22;(4):CD011076. doi: 10.1002/14651858.CD011076.pub2. Review.

PMID:
25900414
7.

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.

Cochrane Database Syst Rev. 2017 Apr 25;4:CD012200. doi: 10.1002/14651858.CD012200.pub2. Review.

PMID:
28440858
8.

Laquinimod for multiple sclerosis.

He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S.

Cochrane Database Syst Rev. 2013 Aug 6;(8):CD010475. doi: 10.1002/14651858.CD010475.pub2. Review.

PMID:
23922214
9.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
10.

Immune therapy of multiple sclerosis--future strategies.

Meuth SG, Göbel K, Wiendl H.

Curr Pharm Des. 2012;18(29):4489-97. Review.

PMID:
22612746
11.

Advances in the treatment of relapsing-remitting multiple sclerosis.

Tanasescu R, Ionete C, Chou IJ, Constantinescu CS.

Biomed J. 2014 Mar-Apr;37(2):41-9. doi: 10.4103/2319-4170.130440. Review.

12.

New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

English C, Aloi JJ.

Clin Ther. 2015 Apr 1;37(4):691-715. doi: 10.1016/j.clinthera.2015.03.001. Epub 2015 Apr 4. Review.

PMID:
25846320
13.

Current and future disease-modifying therapies in multiple sclerosis.

Lim SY, Constantinescu CS.

Int J Clin Pract. 2010 Apr;64(5):637-50. doi: 10.1111/j.1742-1241.2009.02261.x. Review.

PMID:
20456216
14.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Fox EJ.

Clin Ther. 2006 Apr;28(4):461-74. Review.

PMID:
16750460
15.

Current and future therapies targeting the immune system in multiple sclerosis.

Loleit V, Biberacher V, Hemmer B.

Curr Pharm Biotechnol. 2014;15(3):276-96. Review.

PMID:
24938888
16.

An update on new and emerging therapies for relapsing-remitting multiple sclerosis.

Weinstock-Guttman B.

Am J Manag Care. 2013 Nov;19(17 Suppl):s343-54. Review.

17.

Disease-modifying agents in multiple sclerosis.

O'Connor PW, Oh J.

Handb Clin Neurol. 2014;122:465-501. doi: 10.1016/B978-0-444-52001-2.00021-2. Review.

PMID:
24507532
18.

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.

Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui MK, Taneja A, Deniz B.

Curr Med Res Opin. 2014 Apr;30(4):613-27. doi: 10.1185/03007995.2013.863755. Epub 2013 Nov 26. Review.

PMID:
24195574
19.

Classifying PML risk with disease modifying therapies.

Berger JR.

Mult Scler Relat Disord. 2017 Feb;12:59-63. doi: 10.1016/j.msard.2017.01.006. Epub 2017 Jan 6. Review.

PMID:
28283109
20.

Supplemental Content

Support Center